tyrosur 1 mg/1 g prašak za kožu
salveo d.o.o. sarajevo - tirotricin - prašak za kožu - 1 mg/1 g - 1 g praška za kožu sadrži: 1 mg tirotricin
tyrosur 1 mg/1 g gel
salveo d.o.o. sarajevo - tirotricin - gel - 1 mg/1 g - 1 g gela sadrži: 1 mg tirotricin
tyrosur 1 mg/g gel
salveo d.o.o., zavrtnica 17, zagreb, hrvatska - tirotricin - gel - 1 mg/g - urbroj: 1 g gela sadrži 1 mg tirotricina
tyrosur 1 mg/g prašak za kožu
salveo d.o.o., zavrtnica 17, zagreb, hrvatska - tirotricin - prašak za kožu - 1 mg/g - urbroj: 1 g praška sadrži 1 mg tirotricina
spasmex forte 5 mg/1 tableta tableta
novartis ba d.o.o. - trospijum - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg trospijklorida
spasmex 0.2 mg/5 ml rastvor za injekciju
novartis ba d.o.o. - trospijum - rastvor za injekciju - 0.2 mg/5 ml - 5 ml rastvora za injekciju sadrži: 0,2 mg trospijklorida
spasmex forte 5 mg/1 tableta tableta
sandoz d.o.o. - trospijum - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg trospijklorida
tyrosur 1 mg/1 g prašak za kožu
salveo d.o.o. sarajevo - tirotricin - prašak za kožu - 1 mg/1 g - 1 g praška za kožu sadrži: 1 mg tirotricina
tyrosur 1 mg/1 g gel
salveo d.o.o. sarajevo - tirotricin - gel - 1 mg/1 g - 1 g gela sadrži: 1 mg tirotricina
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.